Piper Jaffray analyst Joseph Catanzaro upgraded Seattle Genetics to Overweight from Neutral and raised his price target for the shares to $75 from $64. The company reported Q2 Adcetris revenue of $159M, beating consensus of $149M and reversing the trend of low single-digit quarter-over-quarter growth observed over the last three quarters, Catanzaro tells investors in a research note. Further, the analyst's survey work and conversations with key opinion leaders suggests that enfortumab vedotin is poised to see strong uptake in post-chemo/check-point inhibitors UBC. He believes Seattle Genetics' 2019 guidance of $610M-$640M is "well within reach" while it has the opportunity to report positive data from multiple potential registration trials over the next 12 months.